Business
AGM Statement
AGM Statement.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 6267Y Hemogenyx Pharmaceuticals PLC 07 December 2017 \n\n \nThis announcement contains inside information which, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation (Article 7 of Regulation (EU) No 596/2014.\n \nHemogenyx Pharmaceuticals Plc\n(\"Hemogenyx\" or the \"Company\")\n \nAGM Statement \n \nHemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, will hold its Annual General Meeting today at 10:00am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD. \n \nAhead of the formal business of the AGM, the Board will provide the following strategic update on its activities, technology and products following its successful IPO and Admission to the main market of the London Stock Exchange (LSE) on 5 October 2017:\n \nLaboratory activities are progressing well and to plan, with capacity expanded and the Company's modest scientific recruitment programme almost complete. Activities are focused on working with LakePharma Inc. and Oxford University, its recently announced collaborator, to help progress two distinct but complementary novel proprietary therapies, CDX (a novel bispecific antibody) and HuPHEC (a novel cell therapy), which aim to change the way in which bone marrow/hematopoietic stem cell transplants (BMT/HSCT) are performed and strongly improve their efficacy.\n \nThe appointment of LakePharma provides a strategic partner to help accelerate development of the Company's CDX bispecific antibody (an immunotherapy-class treatment) for patient 'conditioning', the first step required in preparing patients for a BMT. The Company aims to replace current toxic conditioning modalities, which include radiation and chemotherapy, thereby increasing the number of candidate patients for BMT and allowing a greater proportion of these to be successfully conditioned for the subsequent bone marrow transplant. LakePharma, the largest US-based biologics contract research organisation, brings integrated antibody engineering and bioproduction expertise to allow Hemogenyx to advance its CDX product through the necessary preclinical stages to potentially be ready to ent...